
    
      To assess the effect of Gilenya on the rate of decline in bone mass density and expression of
      selected bone turnover biomarkers in ambulatory subject with a relapsing form of Multiple
      Sclerosis compared to control subjects matched for age, race, gender, duration of disease,
      and disability on an alternative FDA approved disease modifying therapy or no therapy at 24
      months compared to baseline.
    
  